Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial
Titel:
Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial
Auteur:
Zhu, Andrew X Kang, Yoon-Koo Yen, Chia-Jui Finn, Richard S Galle, Peter R Llovet, Josep M Assenat, Eric Brandi, Giovanni Pracht, Marc Lim, Ho Yeong Rau, Kun-Ming Motomura, Kenta Ohno, Izumi Merle, Philippe Daniele, Bruno Shin, Dong Bok Gerken, Guido Borg, Christophe Hiriart, Jean-Baptiste Okusaka, Takuji Morimoto, Manabu Hsu, Yanzhi Abada, Paolo B Kudo, Masatoshi